Gene delivery strategies for the treatment of mucopolysaccharidoses

Bibliography

• Giugliani R. Mucopolysacccharidoses: from understanding to treatment, a century of discoveries. Genet Mol Biol 2012;35:924-31
   PubMed Web of Science ®Google Scholar
• de Ru MH, Teunissen QG, van der Lee JH, et al. Capturing phenotypic heterogeneity in MPS I: results of an international consensus procedure. Orphanet J Rare Dis 2012;7-22
   PubMedGoogle Scholar
• Matte U, Yogalingam G, Brooks D, et al. Identification and characterization of 13 new mutations in mucopolysaccharidosis type I patients. Mol Genet Metab 2003;78:37-43
   PubMed Web of Science ®Google Scholar
• Beck M. Therapy for lysosomal storage disorders. IUBMB Life 2010;62:33-40
   PubMed Web of Science ®Google Scholar
• Xu L, Mango RL, Sands MS, et al. Evaluation of pathological manifestations of disease in mucopolysaccharidosis VII mice after neonatal hepatic gene therapy. Mol Ther 2002;6:745-58
   PubMed Web of Science ®Google Scholar
• Giugliani R, Federhen A, Rojas MV, et al. Mucopolysaccharidosis I, II, and VI: brief review and guidelines for treatment. Genet Mol Biol 2010;33:589-604
   PubMed Web of Science ®Google Scholar
• Lau AA, Hannouche H, Rozaklis T, et al. Allogeneic stem cell transplantation does not improve neurological deficits inmucopolysaccharidosis type IIIA mice. Exp Neurol 2010;225:445-54
   PubMed Web of Science ®Google Scholar
• Munoz-Rojas MV, Vieira T, Costa R, et al. Intrathecal enzyme replacement therapy in a patient with mucopolysaccharidosis type I and symptomatic spinal cord compression. Am J Med Genet A 2008;146A:2538-44
   PubMed Web of Science ®Google Scholar
• Ponder KP, Haskins ME. Gene therapy for mucopolysaccharidosis. Expert Opin Biol Ther 2007;7(9):1333-45
   PubMed Web of Science ®Google Scholar
• Lau AA, Rozaklis T, Ibanes S, et al. Helper-dependent canine adenovirus vector-mediated transgene expression in a neurodegenerative lysosomal storage disorder. Gene 2012;491:53-7
   PubMed Web of Science ®Google Scholar
• Baldo G, Wu S, Howe RA, et al. Pathogenesis of aortic dilatation in mucopolysaccharidosis VII mice may involve complement activation. Mol Genet Metab 2011;104:608-19
   PubMed Web of Science ®Google Scholar
• Tessitore A, Faella A, O'Malley T. Biochemical, pathological, and skeletal improvement of mucopolysaccharidosis VI after gene transfer to liver but not to muscle. Mol Ther 2008;16:30-7
   PubMed Web of Science ®Google Scholar
• Metcalf JA, Ma X, Linders B, et al. A self-inactivating gamma-retroviral vector reduces manifestations of mucopolysaccharidosis I in mice. Mol Ther 2010;18:334-42
   PubMed Web of Science ®Google Scholar
• Giugliani R. Newborn screening for lysosomal diseases: current status and potential interface with population medical genetics in Latin America. J Inherit Metab Dis 2012;35:871-7
   PubMed Web of Science ®Google Scholar
• Logan GJ, Alexander IE. Adeno-associated virus vectors: immunobiology and potential use for immune modulation. Curr Gene Ther 2012;12:333-43
   PubMed Web of Science ®Google Scholar
• Wolf DA, Lenander AW, Nan Z, et al. Direct gene transfer to the CNS prevents emergence of neurologic disease in a murine model of mucopolysaccharidosis type I. Neurobiol Dis 2011;43:123-33
   PubMed Web of Science ®Google Scholar
• Ellinwood NM, Ausseil J, Desmaris N, et al. Safe, efficient, and reproducible gene therapy of the brain in the dog models of Sanfilippo and Hurler syndromes. Mol Ther 2011;19(2):251-9
   PubMed Web of Science ®Google Scholar
• Fraldi A, Hemsley K, Crawley A, et al. Functional correction of CNS lesions in an MPS-IIIA mouse model by intracerebral AAV-mediated delivery of sulfamidase and SUMF1 genes. Hum Mol Genet 2007;16:2693-702
   PubMed Web of Science ®Google Scholar
• Heldermon CD, Ohlemiller KK, Herzog ED, et al. Therapeutic efficacy of bone marrow transplant, intracranial AAV-mediated gene therapy, or both in the mouse model of MPS IIIB. Mol Ther 2010;18(5):873-80
   PubMed Web of Science ®Google Scholar
• Haurigot V, Marcó S, Ribera A, et al. Whole body correction of mucopolysaccharidosis IIIA by intracerebrospinal fluid gene therapy. J Clin Invest 2013. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Jung SC, Park ES, Choi EN, et al. Characterization of a novel mucopolysaccharidosis type II mouse model and recombinant AAV2/8 vector-mediated gene therapy. Mol Cells 2010;30:13-18
   PubMed Web of Science ®Google Scholar
• Fu H, Dirosario J, Killedar S, et al. Correction of neurological disease of mucopolysaccharidosis IIIB in adult mice by rAAV9 trans-blood-brain barrier gene delivery. Mol Ther 2011;19:1025-33
   PubMed Web of Science ®Google Scholar
• Ferla R, O'Malley T, Calcedo R, et al. Gene therapy for mucopolysaccharidosis type VI is effective in cats without pre-existing immunity to AAV8. Hum Gene Ther 2013;24:163-9
   PubMed Web of Science ®Google Scholar
• Karolewski BA, Wolfe JH. Genetic correction of the fetal brain increases the lifespan of mice with the severe multisystemic disease mucopolysaccharidosis type VII. Mol Ther 2006;14:14-24
   PubMed Web of Science ®Google Scholar
• Cearley CN, Wolfe JH. A single injection of an adeno-associated virus vector into nuclei with divergent connections results in widespread vector distribution in the brain and global correction of a neurogenetic disease. J Neurosci 2007;27:9928-40
   PubMed Web of Science ®Google Scholar
• Chen YH, Claflin K, Geoghegan JC, Davidson BL. Sialic acid deposition impairs the utility of AAV9, but not peptide-modified AAVs for brain gene therapy in a mouse model of lysosomal storage disease. Mol Ther 2012;20:1393-9
   PubMed Web of Science ®Google Scholar
• Donsante A, Miller DG, Li Y, et al. AAV vector integration sites in mouse hepatocellular carcinoma. Science 2007;317(5837):477
   PubMed Web of Science ®Google Scholar
• Rosas LE, Grieves JL, Zaraspe K, et al. Patterns of scAAV vector insertion associated with oncogenic events in a mouse model for genotoxicity. Mol Ther 2012;20:2098-110
   PubMed Web of Science ®Google Scholar
• Cavazza A, Moiani A, Mavilio F. Mechanisms of retroviral integration and mutagenesis. Hum Gene Ther 2013;24(2):119-31
   PubMed Web of Science ®Google Scholar
• Cavazzana-Calvo M, Fischer A. Gene therapy for severe combined immunodeficiency: are we there yet? J Clin Invest 2007;117:1456-65
   PubMed Web of Science ®Google Scholar
• Stein S, Ott MG, Schultze-Strasser S. Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. Nat Med 2010;16:198-204
   PubMed Web of Science ®Google Scholar
• Mango RL, Xu L, Sands MS, et al. Neonatal retroviral vector-mediated hepatic gene therapy reduces bone, joint, and cartilage disease in mucopolysaccharidosis VII mice and dogs. Mol Genet Metab 2004;82:4-19
   PubMed Web of Science ®Google Scholar
• Wang B, O'Malley TM, Xu L, et al. Expression in blood cells may contribute to biochemical and pathological improvements after neonatal intravenous gene therapy for mucopolysaccharidosis VII in dogs. Mol Genet Metab 2006;87:8-21
   PubMed Web of Science ®Google Scholar
• Traas AM, Wang P, Ma X, et al. Correction of clinical manifestations of canine mucopolysaccharidosis I with neonatal retroviral vector gene therapy. Mol Ther 2007;15:1423-31
   PubMed Web of Science ®Google Scholar
• Chung S, Ma X, Liu Y, et al. Effect of neonatal administration of a retroviral vector expressing alpha-L-iduronidase upon lysosomal storage in brain and other organs in mucopolysaccharidosis I mice. Mol Genet Metab 2007;90:181-92
   PubMed Web of Science ®Google Scholar
• Baldo G, Mayer FQ, Martinelli BZ, et al. Enzyme replacement therapy started at birth improves outcome in difficult-to-treat organs in mucopolysaccharidosis I mice. Mol Genet Metab 2013;109:33-40
   PubMed Web of Science ®Google Scholar
• Ou L, Herzog T, Koniar BL, et al. High-dose enzyme replacement therapy in murine Hurler syndrome. Mol Genet Metab 2013. [Epub ahead of print]
   Google Scholar
• Baldo G, Wozniak DF, Ohlemiller KK, et al. Retroviral-vector-mediated gene therapy to mucopolysaccharidosis I mice improves sensorimotor impairments and other behavioral deficits. J Inherit Metab Dis 2013;36:499-512
   PubMed Web of Science ®Google Scholar
• Bigg PW, Sleeper MM, O'Donnell PA, et al. The effect of neonatal gene therapy with a gamma retroviral vector on cardiac valve disease in mucopolysaccharidosis VII dogs after a decade. Mol Genet Metab 2013;110:311-18
   PubMed Web of Science ®Google Scholar
• Smith LJ, Martin JT, O'Donnell P, et al. Effect of neonatal gene therapy on lumbar spine disease in mucopolysaccharidosis VII dogs. Mol Genet Metab 2012;107:145-52
   PubMed Web of Science ®Google Scholar
• Ponder KP, O'Malley TM, Wang P, et al. Neonatal gene therapy with a gamma retroviral vector in mucopolysaccharidosis VI cats. Mol Ther 2012;20:898-907
   PubMed Web of Science ®Google Scholar
• Papayannakos C, Daniel R. Understanding lentiviral vector chromatin targeting: working to reduce insertional mutagenic potential for gene therapy. Gene Ther 2013;20:581-8
   PubMed Web of Science ®Google Scholar
• Biffi A, Montini E, Lorioli L, et al. Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy. Science 2013;341:1233158
   PubMed Web of Science ®Google Scholar
• Aiuti A, Biasco L, Scaramuzza S, et al. Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome. Science 2013;341:1233151
   PubMed Web of Science ®Google Scholar
• Di Domenico C, Villani GR, Di Napoli D, et al. Intracranial gene delivery of LV-NAGLU vector corrects neuropathology in murine MPS IIIB. Am J Med Genet A 2009;149A:1209-18
   PubMed Web of Science ®Google Scholar
• McIntyre C, Derrick Roberts AL, Ranieri E, et al. Lentiviral-mediated gene therapy for murine mucopolysaccharidosis type IIIA. Mol Genet Metab 2008;93:411-18
   PubMed Web of Science ®Google Scholar
• McIntyre C, Byers S, Anson DS. Correction of mucopolysaccharidosis type IIIA somatic and central nervous system pathology by lentiviral-mediated gene transfer. J Gene Med 2010;12:717-28
   PubMed Web of Science ®Google Scholar
• Macsai CE, Derrick-Roberts AL, Ding X, et al. Skeletal response to lentiviral mediated gene therapy in a mouse model of MPS VII. Mol Genet Metab 2012;106:202-13
   PubMed Web of Science ®Google Scholar
• Camassola M, Braga LM, Delgado-Cañedo A, et al. Nonviral in vivo gene transfer in the mucopolysaccharidosis I murine model. J Inherit Metab Dis 2005;28:1035-43
   PubMed Web of Science ®Google Scholar
• Richard M, Arfi A, Seguin J, et al. Widespread biochemical correction of murine mucopolysaccharidosis type VII pathology by liver hydrodynamic plasmid delivery. Gene Ther 2009;16:746-56
   PubMed Web of Science ®Google Scholar
• Khorsandi SE, Bachellier P, Weber JC, et al. Minimally invasive and selective hydrodynamic gene therapy of liver segments in the pig and human. Cancer Gene Ther 2008;15:225-30
   PubMed Web of Science ®Google Scholar
• Osborn MJ, McElmurry RT, Lees CJ, et al. Minicircle DNA-based gene therapy coupled with immune modulation permits long-term expression of alpha-L-iduronidase in mice with mucopolysaccharidosis type I. Mol Ther 2011;19:450-60
   PubMed Web of Science ®Google Scholar
• Aronovich EL, Bell JB, Khan SA, et al. Systemic correction of storage disease in MPS I NOD/SCID mice using the sleeping beauty transposon system. Mol Ther 2009;17:1136-44
   PubMed Web of Science ®Google Scholar
• Osborn MJ, DeFeo AP, Blazar BR, Tolar J. Synthetic zinc finger nuclease design and rapid assembly. Hum Gene Ther 2011;22:1155-65
   PubMed Web of Science ®Google Scholar
• Matte U, Lagranha VL, de Carvalho TG, et al. Cell microencapsulation: a potential tool for the treatment of neuronopathic lysosomal storage diseases. J Inherit Metab Dis 2011;34:983-90
   PubMed Web of Science ®Google Scholar
• Barsoum SC, Milgram W, Mackay W, et al. Delivery of recombinant gene product to canine brain with the use of microencapsulation. J Lab Clin Med 2003;142:399-413
   PubMed Web of Science ®Google Scholar
• Piller Puicher E, Tomanin R, Salvalaio M, et al. Encapsulated engineered myoblasts can cure Hurler syndrome: preclinical experiments in the mouse model. Gene Ther 2012;19:355-64
   PubMed Web of Science ®Google Scholar
• Baldo G, Mayer FQ, Martinelli B, et al. Intraperitoneal implant of recombinant encapsulated cells overexpressing alpha-L-iduronidase partially corrects visceral pathology in mucopolysaccharidosis type I mice. Cytotherapy 2012;14:860-7
   PubMed Web of Science ®Google Scholar
• Baldo G, Quoos Mayer F, Burin M, et al. Recombinant encapsulated cells overexpressing alpha-L-iduronidase correct enzyme deficiency in human mucopolysaccharidosis type I cells. Cells Tissues Organs 2012;195:323-9
   PubMed Web of Science ®Google Scholar
• Tomanin R, Friso A, Alba S, et al. Non-viral transfer approaches for the gene therapy of mucopolysaccharidosis type II (Hunter syndrome). Acta Paediatr Suppl 2002;91:100-4
   PubMedGoogle Scholar
• Friso A, Tomanin R, Alba S, et al. Reduction of GAG storage in MPS II mouse model following implantation of encapsulated recombinant myoblasts. J Gene Med 2005;7:1482-91
   PubMed Web of Science ®Google Scholar
• Ross CJ, Bastedo L, Maier SA, et al. Treatment of a lysosomal storage disease, mucopolysaccharidosis VII, with microencapsulated recombinant cells. Hum Gene Ther 2000;11:2117-27
   PubMed Web of Science ®Google Scholar
• Ross CJ, Ralph M, Chang PL, et al. Somatic gene therapy for a neurodegenerative disease using microencapsulated recombinant cells. Exp Neurol 2000;166:276-86
   PubMed Web of Science ®Google Scholar
• Nakama H, Ohsugi K, Otsuki T, et al. Encapsulation cell therapy for mucopolysaccharidosis type VII using genetically engineered immortalized human amniotic epithelial cells. Tohoku J Exp Med 2006;209:23-32
   PubMed Web of Science ®Google Scholar
• Mazumder MA, Burke NA, Shen F, et al. Core-cross-linked alginate microcapsules for cell encapsulation. Biomacromolecules 2009;10:1365-73
   PubMed Web of Science ®Google Scholar
• Baruch L, Benny O, Gilert A, et al. Alginate-PLL cell encapsulation system Co-entrapping PLGA-microspheres for the continuous release of anti-inflammatory drugs. Biomed Microdevices 2009;11:1103-13
   PubMed Web of Science ®Google Scholar
• Lagranha VL, de Carvalho TG, Giugliani R, Matte U. Treatment of MPS I mice with microencapsulated cells overexpressing IDUA: effect of the prednisolone administration. J Microencapsul 2013;30:383-9
   PubMed Web of Science ®Google Scholar
• Langford-Smith A, Wilkinson FL, Langford-Smith KJ, et al. Hematopoietic stem cell and gene therapy corrects primary neuropathology and behavior in mucopolysaccharidosis IIIA mice. Mol Ther 2012;20:1610-21
   PubMed Web of Science ®Google Scholar
• Visigalli I, Delai S, Politi LS, et al. Gene therapy augments the efficacy of hematopoietic cell transplantation and fully corrects mucopolysaccharidosis type I phenotype in the mouse model. Blood 2010;116:5130-9
   PubMed Web of Science ®Google Scholar
• Ma X, Liu Y, Tittiger M, et al. Improvements in mucopolysaccharidosis I mice after adult retroviral vector-mediated gene therapy with immunomodulation. Mol Ther 2007;15:889-902
   PubMed Web of Science ®Google Scholar
• Di Domenico C, Villani GR, Di Napoli D, et al. Gene therapy for a mucopolysaccharidosis type I murine model with lentiviral-IDUA vector. Hum Gene Ther 2005;16:81-90
   PubMed Web of Science ®Google Scholar
• Gao C, Sands MS, Haskins ME, Ponder KP. Delivery of a retroviral vector expressing human beta-glucuronidase to the liver and spleen decreases lysosomal storage in mucopolysaccharidosis VII mice. Mol Ther 2000;2:233-44
   PubMed Web of Science ®Google Scholar